The short version of synaptogenesis fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-01 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Kipa-Williams explained that Marilyn "stumbles" across the family living out of their car on her way to work, and invites them to stay with her, but they initially turn her offer down. Gemma's pride stops her from accepting Marilyn's offer, until she realises that the family needs to come first. When John returns home, he is surprised to find the family in his house. Kipa-Williams believed John was jealous of Ari's connection with Marilyn, saying "John doesn't like the fact that Marilyn has this bond with Ari. He wishes she shared that connection with him, and John starts to grow jealous – it gets heated a few times." Symons explained that for Marilyn, letting the family stay with her is her way of paying back Ari for comforting her during the siege. She sees that the family is struggling and wants to help them settle in the Bay. John's opposition causes problems in his marriage, as he does not understand why Marilyn would invite the family to stay. Symons was excited about the Parata's introduction, as it gave everyone "a new energy to play off." The fractious nature of Ari and Tane's relationship comes to a head when they fight over their nephew. After Nikau gets fed up living with Ari and Gemma, he seeks out his uncle and stays the night at his place. When Tane drops him off in the morning, Ari accuses Tane of being "a bad influence" and the pair have a physical altercation by the road. Following a break-in at the Pier Diner, Constable Colby Thorne (Tim Franklin) is convinced the Paratas had something to do with it and he becomes "desperate" to pin the crime on them.
=== First treatment === The recommended first treatment is a four- to six-week course combining stretching, foot taping (using a special tape around the foot for supporting the arch) and individually tailored education on footwear and other management options. Reduction in pain and stress involve strengthening foot muscles that support the arches through barefoot exercising, without footwear, compared to exercising in common footwear. Supportive insoles are a common conservative treatment. Insoles that provide arch support and cushioning may reduce strain on the plantar fascia by improving foot alignment and distributing plantar pressure more evenly during standing and walking. This reduction can help alleviate discomfort, particularly in individuals who engage in prolonged standing or repetitive weight-bearing activities.
Aspergillus parasiticus is a fungus belonging to the genus Aspergillus. This species is an unspecialized saprophytic mold, mostly found outdoors in areas of rich soil with decaying plant material as well as in dry grain storage facilities. Often confused with the closely related species, A. flavus, A. parasiticus has defined morphological and molecular differences. Aspergillus parasiticus is one of three fungi able to produce the mycotoxin, aflatoxin, one of the most carcinogenic naturally occurring substances. Environmental stress can upregulate aflatoxin production by the fungus, which can occur when the fungus is growing on plants that become damaged due to exposure to poor weather conditions, during drought, by insects, or by birds. In humans, exposure to A. parasiticus toxins can cause delayed development in children and produce serious liver diseases and/or hepatic carcinoma in adults. The fungus can also cause the infection known as aspergillosis in humans and other animals. A. parasiticus is of agricultural importance due to its ability to cause disease in corn, peanut, and cottonseed.
Robert Lax (1938), minimalist poet Ed Rice (1940), Beat Generation writer Walter Farley (1941), author of The Black Stallion and its many sequels Thomas Gallagher (1941), winner of a 1960 Edgar Award and National Book Award for Fiction finalist Gerald Green (1942), writer of Holocaust and The Last Angry Man, co-creator of NBC's The Today Show Richard de Mille* (1944), writer and investigative journalist, son of director Cecil B. DeMille Jack Kerouac* (1944), Beat Generation author of On the Road Leonard Koppett (1944), sportswriter; recipient of the J. G. Taylor Spink Award and the Curt Gowdy Media Award Walter Wager (1944), mystery writer whose book 58 Minutes was adapted into Die Hard 2 Herbert Gold (1946), Beat Generation novelist Daniel Hoffman (1947), poet; 22nd United States Poet Laureate Hiag Akmakjian (1948), author Allen Ginsberg (1948), Beat Generation poet; author of Howl Frederick Karl (1948), literary biographer famous for his work on Joseph Conrad Stanley Loomis (1948), American expatriate writer Charles Simmons (1948), author, winner of the 1965 William Faulkner Foundation Award for notable first novel Louis Simpson (1948), poet; winner of the 1964 Pulitzer Prize for Poetry John Clellon Holmes (1949), Beat Generation novelist, Go John Hollander (1950), poet, MacArthur Fellow and winner of the Bollingen Prize Richard Howard (1951), translator and winner of the Pulitzer Prize for Poetry Anthony Robinson (1953), English professor and novelist Ralph Schoenstein (1953), humorist Dan Wakefield (1955), novelist, journalist, screenwriter John J.
Sources: en.wikipedia.org
== Medical uses == Mineralocorticoid receptor antagonists are diuretic drugs that work primarily on the kidneys. They decrease sodium reabsorption, which leads to increased water excretion by the kidneys. By regulating water excretion, mineralocorticoid receptor antagonists lower blood pressure and reduce fluid around the heart which can be very beneficial in some cardiovascular conditions. Mineralocorticoid receptor antagonists have been used for many clinical conditions in the cardiovascular system. It has proven beneficial for diseases like primary aldosteronism, primary and resistant hypertension, heart failure and chronic kidney disease. They are often used with other medications, such as ACE inhibitors or beta blockers.
The Unitized Group Ration – A (UGR-A) is the successor to the A-ration, and consists of perishable entrées intended to be prepared in a field kitchen. The UGR-A is the only UGR with frozen food, and requires refrigeration to store and prepare. The UGR-A has 7 breakfast menus and 14 lunch/dinner menus. Each meal provides an average of 1,450 kcal. Each UGR-A module contains 50 meals, with each pallet holding 600 meals. UGR-A modules have a minimum shelf life of 9 months outside the contiguous U.S. and 3 months within the contiguous U.S., at 80 °F (26.6 °C) for semi-perishable modules and 0 °F (-17.7 °C) for perishable modules.
=== Economy, development, and resource factors === A 2018 study found that "oil price shocks are seen to promote coups in onshore-intensive oil countries, while preventing them in offshore-intensive oil countries". The study argues that states which have onshore oil wealth tend to build up their military to protect the oil, whereas states do not do that for offshore oil wealth. A 2020 study found that elections had a two-sided impact on coup attempts, depending on the state of the economy. During periods of economic expansion, elections reduced the likelihood of coup attempts, whereas elections during economic crises increased the likelihood of coup attempts. A 2021 study found that oil wealthy nations see a pronounced risk of coup attempts but these coups are unlikely to succeed. On the contrary, a 2014 study of 18 Latin American countries in the 20th century found that coup frequency does not vary with development levels, economic inequality, or the rate of economic growth.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.